Round-up of INTERPHEX 2025
Author: Alexander Zirlin (RX Global; London, UK)
INTERPHEX 2025 (April 1–3, 2025; NY, USA) proved once again that it’s more than a trade show—it’s a launchpad for the future of pharmaceutical and biopharmaceutical manufacturing. This year’s conference program featuring 45+ curated education sessions delivered an incredible lineup of thought leaders, disruptors and industry experts that spoke on some of the leading trends and topics shaping the industry.
Here are just a few of the standout sessions that sparked conversations and gave us real food for thought:
AI-powered data: revolutionizing real-time release and quality by design
This keynote explored how AI is shifting real-time release from a future goal to a present capability. From predictive modeling to adaptive quality frameworks, the session highlighted how digital tools are becoming essential pillars of modern Quality by Design (QbD) strategies.
Business continuity in biopharmaceutical supply chains during COVID-19
A compelling reflection on lessons learned through crisis. The speakers walked us through not just how companies adapted, but how the pandemic redefined what resilience and preparedness look like in pharma supply chains today.
Essential drug delivery output is the new essential performance requirement
In this eye-opening keynote, we were reminded that formulation excellence isn’t just about what goes in—it’s about what consistently comes out. The bar has been raised for performance-driven delivery systems.
Optimizing cleaning validations: analytics, contamination control and sustainability strategies
This panel delivered a trifecta: improved outcomes, cost efficiency and environmental responsibility. From data-driven cleaning validation to sustainable materials, the takeaways were clear—optimization is no longer optional.
Some of the conference talk highlights.
Utilizing FDA data for regulatory trends within advanced manufacturing
Regulatory foresight took center stage as this session demonstrated how publicly-available FDA data can be harnessed to track, predict and stay ahead of compliance expectations in an increasingly complex manufacturing environment.
Innovations in sustainable, highly efficient GLP-1 agonist production sites
This late-breaking session was a standout for anyone invested in therapeutic scale-up. Speakers showcased how sustainability and scalability can—and must—coexist in the next wave of GLP-1 facility design.
The Learning Lab covered everything from supply chain strategy to AI applications in pharma — plus headshot booths, LinkedIn reviews and a packed Fireside Chat.
INTERPHEX remains to be a crucial platform for the pharmaceutical and biotechnology industries. This year’s conference showcased major developments in advanced manufacturing, AI, sustainability and cell and gene therapy, while continuing to drive conversations within the compliance and supply chain sectors.
Planning for INTERPHEX 2026 is already underway with confirmed dates of April 21–23, 2026 and returning to the Javits Center (NY, USA). For more information about the 2026 Show, please visit www.INTERPHEX.com or click the button below.
